Figure 1 [E06]

DNA impacts immune balance and tumor growth. Dying cells in the developing Tumor Microenvironment (TME) release DNA, which is sensed to induce IDO and suppress anti-tumor immunity (red highlights). Immunotherapy incites anti-tumor immunity (green highlights) to promote tumor regression but DNA driven immune suppression may re-establish after therapy. Increased pain is also a potential consequence of elevated IDO activity in the tolerogenic TME. Elevated tumor immunogenicity may reduce barriers to therapy by enhancing immunogenic responses to DNA in the TME.